BR112014032264A8 - Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo - Google Patents

Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo

Info

Publication number
BR112014032264A8
BR112014032264A8 BR112014032264A BR112014032264A BR112014032264A8 BR 112014032264 A8 BR112014032264 A8 BR 112014032264A8 BR 112014032264 A BR112014032264 A BR 112014032264A BR 112014032264 A BR112014032264 A BR 112014032264A BR 112014032264 A8 BR112014032264 A8 BR 112014032264A8
Authority
BR
Brazil
Prior art keywords
vascular permeability
pharmaceutically acceptable
acceptable salt
active ingredient
composition
Prior art date
Application number
BR112014032264A
Other languages
English (en)
Other versions
BR112014032264A2 (pt
Inventor
Yeon Kim Ji
Hee Suh Won
Original Assignee
Univ Ajou Ind Academic Coop Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ajou Ind Academic Coop Found filed Critical Univ Ajou Ind Academic Coop Found
Publication of BR112014032264A2 publication Critical patent/BR112014032264A2/pt
Publication of BR112014032264A8 publication Critical patent/BR112014032264A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição para tratamento ou prevenção de doenças relacionadas à permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo. a presente invenção refere-se a uma composição farmacêutica para tratar permeabilidade vascular, ou prevenir uma doença relacionada à que contém imatinibe ou um sal farmaceuticarnente aceitável respectivo corno um ingrediente ativo, e, mais particularmente, a uma composição farmacêutica para tratar ou prevenir uma doença relacionada à permeabilidade vascular, que contém, corno um ingrediente ativo, imatinibe ou um sal farmaceuticarnente aceitável respectivo que foi utilizado como um agente terapêutico para leucemia mieloide crônica na técnica prévia e a um método de tratamento de uma doença relacionada à permeabilidade vascular utilizando a composição.
BR112014032264A 2012-06-18 2013-06-10 Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo BR112014032264A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120065193A KR101386697B1 (ko) 2012-06-18 2012-06-18 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
PCT/KR2013/005068 WO2013191401A1 (ko) 2012-06-18 2013-06-10 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 질환의 치료 또는 예방용 조성물

Publications (2)

Publication Number Publication Date
BR112014032264A2 BR112014032264A2 (pt) 2017-06-27
BR112014032264A8 true BR112014032264A8 (pt) 2022-03-03

Family

ID=49768959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032264A BR112014032264A8 (pt) 2012-06-18 2013-06-10 Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo

Country Status (11)

Country Link
US (1) US9511068B2 (pt)
EP (1) EP2862573B1 (pt)
JP (1) JP6030234B2 (pt)
KR (1) KR101386697B1 (pt)
CN (2) CN107496426A (pt)
BR (1) BR112014032264A8 (pt)
CA (1) CA2876926C (pt)
ES (1) ES2668908T3 (pt)
MX (1) MX365021B (pt)
RU (2) RU2014151382A (pt)
WO (1) WO2013191401A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101498973B1 (ko) 2013-11-21 2015-03-05 현대모비스(주) 차량용 주차 지원 시스템 및 방법
GB201401005D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Inhibitor
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0201882D0 (en) 2002-01-28 2002-03-13 Novartis Ag Organic compounds
AU2003226349B2 (en) 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US8637553B2 (en) * 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
KR101471732B1 (ko) 2003-08-27 2014-12-16 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
GB0421438D0 (en) * 2004-09-27 2004-10-27 Astrazeneca Ab Combination therapy
MY148676A (en) * 2004-06-04 2013-05-31 Bioniche Life Sciences Inc Use of imatinib to treat liver disorders and viral infections
US20080015205A1 (en) 2004-09-27 2008-01-17 Wedge Stephen R Cancer Combination Therapy Comprising Azd2171 and Imatinib
BRPI0516052A (pt) 2004-09-27 2008-08-19 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
WO2006041976A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
PL1893213T3 (pl) 2005-06-03 2010-08-31 Novartis Ag Kombinacja związków pirymidyloaminobenzamidowych i imatinibu do leczenia lub profilaktyki chorób proliferacyjnych
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
CA2667720A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
PL2305263T3 (pl) 2007-06-07 2012-12-31 Novartis Ag Stabilizowane amorficzne formy mesylanu imatinibu
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물

Also Published As

Publication number Publication date
RU2018128737A (ru) 2019-03-14
CN104582704A (zh) 2015-04-29
MX2014015785A (es) 2015-06-10
JP2015520226A (ja) 2015-07-16
CN107496426A (zh) 2017-12-22
US9511068B2 (en) 2016-12-06
EP2862573B1 (en) 2018-03-07
RU2014151382A (ru) 2016-08-10
CA2876926A1 (en) 2013-12-27
JP6030234B2 (ja) 2016-11-24
BR112014032264A2 (pt) 2017-06-27
EP2862573A4 (en) 2016-01-27
MX365021B (es) 2019-05-20
EP2862573A1 (en) 2015-04-22
KR101386697B1 (ko) 2014-04-18
US20150320750A1 (en) 2015-11-12
RU2018128737A3 (pt) 2019-03-14
CA2876926C (en) 2017-04-04
KR20130141998A (ko) 2013-12-27
ES2668908T3 (es) 2018-05-23
WO2013191401A1 (ko) 2013-12-27

Similar Documents

Publication Publication Date Title
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CR20190073A (es) FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112015018168A2 (pt) inibidores de rock suaves
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
AR101740A1 (es) Terapia de combinación y composiciones
MX2015010829A (es) Compuestos terapeuticos y sus usos.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]